Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04899232 Terminated - Covid19 Clinical Trials

Antithrombin III in Infectious Disease Caused by COVID-19

Start date: July 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

NCT ID: NCT04894266 Terminated - COVID-19 Infection Clinical Trials

An Open-Label Study of Apabetalone in Covid Infection

Start date: January 14, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

NCT ID: NCT04891133 Terminated - COVID-19 Clinical Trials

EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Bari-SolidAct
Start date: June 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to hospital with COVID-19. The platform is designed for running phase 2 and phase 3 trials, and with modular data capture (end point/safety data, biobanking, add-on studies) depending on the capacity of participating sites. The study consists of two parts with different primary end points depending on disease stage: EU SolidAct part A includes hospitalized patients with moderate disease, whereas EU SolidAct part B includes hospitalized patients with severe and critical disease.

NCT ID: NCT04889040 Terminated - COVID-19 Clinical Trials

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

MORNINGSKY
Start date: April 28, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.

NCT ID: NCT04884295 Terminated - Covid19 Clinical Trials

Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19

Start date: August 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a 2 part study where the first part (Phase 1) evaluates the safety of XVR011 and aims to identify the recommended Phase 2 dose. The second part (Phase 2) follows after the part 1 and evaluates whether XVR011 added to standard of care in patients hospitalised for mild to moderate COVID-19 is a safe, well tolerated, and effective treatment. Part 1 (Phase 1) is completed as per protocol. The sponsor does not intend to start Part 2 (Phase 2) due to change in company strategy for phase 2 design.

NCT ID: NCT04883138 Terminated - COVID-19 Clinical Trials

Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients

Start date: May 24, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.

NCT ID: NCT04880109 Terminated - COVID-19 Clinical Trials

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

Start date: October 20, 2021
Phase: Phase 2
Study type: Interventional

This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm.

NCT ID: NCT04878211 Terminated - Clinical trials for Relapsing Multiple Sclerosis (RMS)

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Start date: June 10, 2021
Phase: Phase 4
Study type: Interventional

This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or glatiramer acetate.

NCT ID: NCT04877743 Terminated - Clinical trials for Coronavirus Disease 2019 (COVID-19)

Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222

COVID-19
Start date: May 31, 2021
Phase:
Study type: Observational

This is a Phase IV real-world, observational, non-interventional, prospective cohort study of adults vaccinated with AZD1222. The purpose of this study is to assess the safety and tolerability of AZD1222 in adults vaccinated in real-world settings.

NCT ID: NCT04877002 Terminated - Covid19 Clinical Trials

Performance Study of SONA Saliva C-19 Rapid Test

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method